Condition: Endometrial Cancer · Gastric Cancer · Metastatic Castration-resistant Prostate Cancer · Sponsor: AstraZeneca
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Los Angeles, California, United States | Recruiting |
| Research Site | San Diego, California, United States | Withdrawn |
| Research Site | Santa Rosa, California, United States | Recruiting |
| Research Site | Muncie, Indiana, United States | Withdrawn |
| Research Site | Kansas City, Kansas, United States | Withdrawn |
| Research Site | Boston, Massachusetts, United States | Withdrawn |
| Research Site | Boston, Massachusetts, United States | Completed |
| Research Site | Grand Rapids, Michigan, United States | Recruiting |
| Research Site | East Brunswick, New Jersey, United States | Recruiting |
| Research Site | Albuquerque, New Mexico, United States | Recruiting |
| Research Site | Commack, New York, United States | Recruiting |
| Research Site | Cincinnati, Ohio, United States | Recruiting |
+ 84 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05489211